The impact of the policy on businesses and users

Enterprises: Policies provide a solid backing for corporate innovation and development. The special review process for innovative medical devices has significantly shortened the approval cycle for high-end endoscopes, enabling enterprises to bring their R&D achievements to market more quickly—for instance, Weitong’s intelligent-focus endoscope has been swiftly approved and launched. Meanwhile, the establishment of standardized technical organizations and the dynamic adjustment of product categories have defined clear boundaries for corporate R&D, reducing its randomness and uncertainty. At the same time, centralized procurement and medical insurance policies are driving enterprises toward transformation. DRG/DIP Under the reform of payment methods, medical institutions are favoring cost-effective equipment, prompting companies to shift from simply selling equipment to offering “equipment + services.” +  Consumables +  The integrated “service” model, coupled with preferential procurement policies at the grassroots level, has also prompted companies to focus their R&D efforts on developing simplified endoscopic products tailored specifically for grassroots settings. Moreover, enhanced post-market surveillance requirements have led companies to increase their investments in areas such as quality testing and adverse event tracing, thereby raising compliance costs.

For medical institutions, the policy has accelerated the adoption of high-end medical equipment. In particular, primary-level medical institutions can take advantage of favorable policies to procure high-quality, domestically produced endoscopes at lower prices, thereby enhancing their diagnostic and treatment capabilities at the grassroots level. Moreover, the clearly defined technical review standards have reduced the compliance risks associated with medical institutions’ equipment procurement. For patients, the policy-driven substitution of imported products with domestically manufactured alternatives has made endoscopic examinations and treatments more affordable. After certain endoscopic products were included in centralized procurement, patients’ medical expenses have been significantly reduced. At the same time, strengthened regulatory oversight has ensured product quality, minimizing the risk of equipment malfunctions during endoscopic procedures and further enhancing patient safety.